Supernus Pharmaceuticals Target of Unusually Large Options Trading (SUPN)

Supernus Pharmaceuticals Inc (NASDAQ:SUPN) was the target of some unusual options trading on Wednesday. Investors acquired 906 call options on the stock. This represents an increase of approximately 1,712% compared to the average daily volume of 50 call options.

In other news, VP Padmanabh P. Bhatt sold 20,000 shares of the company’s stock in a transaction on Wednesday, January 17th. The stock was sold at an average price of $44.98, for a total value of $899,600.00. Following the completion of the sale, the vice president now owns 32,500 shares in the company, valued at $1,461,850. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, VP Victor Vaughn sold 5,750 shares of the company’s stock in a transaction on Friday, January 12th. The shares were sold at an average price of $45.03, for a total value of $258,922.50. Following the completion of the sale, the vice president now owns 15,094 shares of the company’s stock, valued at approximately $679,682.82. The disclosure for this sale can be found here. In the last 90 days, insiders sold 145,750 shares of company stock valued at $6,173,173. Insiders own 6.70% of the company’s stock.

Institutional investors have recently made changes to their positions in the stock. Teachers Advisors LLC lifted its stake in Supernus Pharmaceuticals by 6.9% in the 2nd quarter. Teachers Advisors LLC now owns 466,060 shares of the specialty pharmaceutical company’s stock worth $20,087,000 after acquiring an additional 29,939 shares in the last quarter. Royal Bank of Canada lifted its stake in Supernus Pharmaceuticals by 790.8% in the 2nd quarter. Royal Bank of Canada now owns 271,451 shares of the specialty pharmaceutical company’s stock worth $11,699,000 after acquiring an additional 240,978 shares in the last quarter. First Trust Advisors LP purchased a new stake in Supernus Pharmaceuticals in the 3rd quarter worth about $2,255,000. Pictet Asset Management Ltd. lifted its stake in Supernus Pharmaceuticals by 438.7% in the 3rd quarter. Pictet Asset Management Ltd. now owns 491,283 shares of the specialty pharmaceutical company’s stock worth $19,651,000 after acquiring an additional 400,083 shares in the last quarter. Finally, State Street Corp lifted its stake in Supernus Pharmaceuticals by 3.1% in the 2nd quarter. State Street Corp now owns 1,397,484 shares of the specialty pharmaceutical company’s stock worth $60,230,000 after acquiring an additional 42,165 shares in the last quarter. 98.22% of the stock is owned by hedge funds and other institutional investors.

Shares of Supernus Pharmaceuticals (SUPN) opened at $46.90 on Friday. Supernus Pharmaceuticals has a fifty-two week low of $23.10 and a fifty-two week high of $50.04. The company has a market capitalization of $2,400.00, a price-to-earnings ratio of 42.64 and a beta of 1.17.

Supernus Pharmaceuticals (NASDAQ:SUPN) last announced its earnings results on Monday, November 6th. The specialty pharmaceutical company reported $0.29 EPS for the quarter, beating the consensus estimate of $0.27 by $0.02. Supernus Pharmaceuticals had a return on equity of 26.37% and a net margin of 20.98%. The business had revenue of $80.40 million during the quarter, compared to the consensus estimate of $78.74 million. Supernus Pharmaceuticals’s quarterly revenue was up 41.5% on a year-over-year basis. sell-side analysts predict that Supernus Pharmaceuticals will post 1.07 EPS for the current fiscal year.

Several brokerages have recently weighed in on SUPN. B. Riley restated a “buy” rating and issued a $54.00 price objective on shares of Supernus Pharmaceuticals in a report on Thursday. Zacks Investment Research downgraded Supernus Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Friday, January 12th. BidaskClub raised Supernus Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Thursday, January 11th. Janney Montgomery Scott raised Supernus Pharmaceuticals from a “neutral” rating to a “buy” rating and set a $47.00 target price for the company in a report on Monday, December 4th. Finally, ValuEngine downgraded Supernus Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Friday, December 1st. Three analysts have rated the stock with a hold rating, eight have given a buy rating and one has issued a strong buy rating to the stock. The company currently has a consensus rating of “Buy” and a consensus target price of $49.90.

TRADEMARK VIOLATION WARNING: “Supernus Pharmaceuticals Target of Unusually Large Options Trading (SUPN)” was first reported by American Banking News and is the property of of American Banking News. If you are viewing this report on another publication, it was illegally copied and republished in violation of US and international copyright & trademark law. The correct version of this report can be accessed at https://www.americanbankingnews.com/2018/01/20/supernus-pharmaceuticals-target-of-unusually-large-options-trading-supn.html.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc is a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. The Company offers Oxtellar XR (extended-release oxcarbazepine) and Trokendi XR (extended-release topiramate), its two treatments for patients with epilepsy.

Receive News & Ratings for Supernus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Supernus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply